Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults
뉴질랜드 성인에서 BNT162b2 COVID-19 백신의 면역원성
Article
[키워드] age
All participant
All participants
analysed
anti-S IgG
Antibody Response
baseline
Beta
BMI
BNT162b2
BNT162b2 mRNA vaccine
BNT162b2 vaccine
Cellular immune response
cellular immune responses
co-morbidities
Cohort
COVID-19
COVID-19 disease
COVID-19 vaccine
declined
Delta
diabete
diabetes
diabetics
disease
dose
enrichment
Ethnic groups
female
Gender
General population
IgG
immune response
immune responses
immunoassay
immunogenicity
in vitro
International
Lower
Māori
median age
Microparticle
morbidities
morbidity
naïve
neutralise
neutralising antibody
neutralising response
neutralising responses
neutralizing capacity
New
obesity
of BNT162b2
Older
Older adults
omicron
other variant
other variants
Pacific Islander
Population
prospective cohort study
pulmonary disease
Quantitative
recipient
representation
response
risk
robust
SARS-CoV-2 vaccine
second dose
second vaccination
serious COVID-19
seroconverted
serum sample
serum samples
strain
the vaccine
Vaccine
vaccine.
variant
Viral
viral neutralisation
Wuhan
[DOI] 10.1016/j.vaccine.2022.07.009 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.vaccine.2022.07.009 PMC 바로가기 [Article Type] Article